Cholinesterase inhibition in Alzheimer's disease: Is specificity the answer?

Journal of Alzheimer's Disease

Volumn 42, Issue 2, 2014, Pages 379-384

  Macdonald, Ian R ^a   Rockwood, Kenneth ^b   Martin, Earl ^c   Darvesh, Sultan ^a,b,c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c MOUNT SAINT VINCENT UNIVERSITY   (Canada)

Author keywords

( ) huperzine A; Acetylcholinesterase; bisnorcymserine; butyrylcholinesterase; donepezil; rivastigmine

Indexed keywords

CHOLINESTERASE; DONEPEZIL; GALANTAMINE; HUPERZINE A; PHENSERINE; PHYSOSTIGMINE; PROFENAMINE; RIVASTIGMINE; TACRINE; CHOLINESTERASE INHIBITOR; NEUROLEPTIC AGENT;

ACETYLCHOLINE BRAIN LEVEL; ALZHEIMER DISEASE; ARTICLE; CHOLINESTERASE INHIBITION; COGNITIVE DEFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUPERZIA; HUPERZIA SERATTA; LONG TERM POTENTIATION; MINI MENTAL STATE EXAMINATION; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL (TOPIC); ENZYMOLOGY;

ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; HUMANS;

EID: 84916934135     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140219     Document Type: Article

References (47)

1. Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2, 1403.
2. Bartus RT, Dean RL, 3rd, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217, 408-414.
3. Coyle JT, Price DL, DeLongMR(1983) Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 219, 1184-1190.
4. Birks J (2006) Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev, CD005593.
5. Bracco L, Bessi V, Padiglioni S, Marini S, Pepeu G (2014) Do cholinesterase inhibitors act primarily on attention deficit? A naturalistic study in Alzheimer's disease patients. J Alzheimers Dis 40, 737-742.
6. Silver A (1974) The Biology of Cholinesterases, Elsevier, Amsterdam.
7. Darvesh S, Hopkins DA, Geula C (2003) Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 4, 131-138.
8. Cerbai F, Giovannini MG, Melani C, Enz A, Pepeu G (2007) N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: A comparison with donepezil and rivastigmine. Eur J Pharmacol 572, 142-150.
9. Greig NH, Utsuki T, Ingram DK, Wang Y, Pepeu G, Scali C, Yu QS, Mamczarz J, Holloway HW, Giordano T, Chen D, Furukawa K, Sambamurti K, Brossi A, Lahiri DK(2005) Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad SciUSA102, 17213-17218.
10. Li J, Wu HM, Zhou RL, Liu GJ, Dong BR (2008) Huperzine A for Alzheimer's disease. Cochrane Database Syst Rev, CD005592.
11. Kapogiannis D (2013) Bisnorcymserine in healthy adult volunteers, NCT01747213, ClinicalTrials.gov.
12. Davis KL, Mohs RC (1982) Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry 139, 1421-1424.
13. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A (1986) Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 315, 1241-1245.
14. Darvesh S, Walsh R, Kumar R, Caines A, Roberts S, Magee D, Rockwood K, Martin E (2003) Inhibition of human cholinesterases by drugs used to treat Alzheimer disease. Alzheimer Dis Assoc Disord 17, 117-126.
15. Rakonczay Z (2003) Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biol Hung 54, 183-189.
16. Lahiri DK, Lewis S, Farlow MR (1994) Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. J Neurosci Res 37, 777-787.
17. Lahiri DK, Farlow MR, Sambamurti K (1998) The secretion of amyloid beta-peptides is inhibited in the tacrine-treated human neuroblastoma cells. Brain Res Mol Brain Res 62, 131-140.
18. Bailey JA, Lahiri DK (2010) A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease. J Neurochem 112, 843-853.
19. Bailey JA, Ray B, Greig NH, Lahiri DK (2011) Rivastigmine lowers A and increases sAPP levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One 6, e21954.
20. Shaw KT, Utsuki T, Rogers J, Yu QS, Sambamurti K, Brossi A, Ge YW, Lahiri DK, Greig NH (2001) Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci U S A 98, 7605-7610.
21. Utsuki T, Yu QS, Davidson D, Chen D, Holloway HW, Brossi A, Sambamurti K, Lahiri DK, Greig NH, Giordano T (2006) Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide. J Pharmacol Exp Ther 318, 855-862.
22. Fang L, Jumpertz S, ZhangY, Appenroth D, Fleck C, Mohr K, Trankle C, DeckerM(2010) Hybrid molecules from xanomeline and tacrine: Enhanced tacrine actions on cholinesterases and muscarinic M1 receptors. J Med Chem 53, 2094-2103.
23. Greig NH, Reale M, Tata AM (2013) New pharmacological approaches to the cholinergic system: An overview on muscarinic receptor ligands and cholinesterase inhibitors. Recent Pat CNS Drug Discov 8, 123-141.
24. Liu JS, Zhu YL, Yu CM, Zhou YZ, Han YY, Wu FW, Qi BF (1986) The structures of huperzine A and B, two new alkaloids exhibiting anticholinesterase activity. Can J Chem 64, 837-841.
25. Valenta Z, Yoshimura H, Rogers EF, Ternbah M, Wiesner K (1960) The structure of selagine. Tetrahedron Lett 10, 26-33.
26. Yoshimura H, Valenta Z, Wiesner K (1960) A rigorous proof of the selagine structure. Tetrahedron Lett 12, 14-17.
27. Ayer WA, Browne LM, Orszanska H, Valenta Z, Liu J-S (1989) Alkaloids of Lycopodium selago. On the identity of selagine with huperzine A and the structure of a related alkaloid. Can J Chem 67, 1538-1540.
28. Wang YE, Yue DX, Tang X (1986) Anti-cholinesterase activity of huperzine A. Acta Pharmachol Sinica 7, 110-113.
29. Ashani Y, Peggins JO, 3rd, Doctor BP (1992) Mechanism of inhibition of cholinesterases by huperzine A. Biochem Biophys Res Commun 184, 719-726.
30. Saxena A, Qian N, Kovach IM, Kozikowski AP, Pang YP, Vellom DC, Radic Z, Quinn D, Taylor P, Doctor BP (1994) Identification of amino acid residues involved in the binding of Huperzine A to cholinesterases. Protein Sci 3, 1770-1778.
31. Ma X, Gang DR (2004) The Lycopodium alkaloids. Nat Prod Rep 21, 752-772.
32. Carlier PR, Du DM, Han YF, Liu J, Perola E, Williams ID, Pang YP (2000) Dimerization of an inactive fragment of huperzine a produces a drug with twice the potency of the natural product. Angew Chem Int Ed Engl 39, 1775-1777.
33. Camps P, El Achab R, Morral J, Munoz-Torrero D, Badia A, Banos JE, Vivas NM, Barril X, Orozco M, Luque FJ (2000) New tacrine-huperzine A hybrids (huprines): Highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. J Med Chem 43, 4657-4666.
34. Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, Jin S, Thomas R, Aisen PS (2011)Aphase II trial of huperzine Ain mild to moderate Alzheimer disease. Neurology 76, 1389-1394.
35. Winblad B, Giacobini E, Frolich L, Friedhoff LT, Bruinsma G, Becker RE, Greig NH (2010) Phenserine efficacy in Alzheimer's disease. J Alzheimers Dis 22, 1201-1208.
36. Gao X, Zheng CY, Yang L, Tang XC, Zhang HY (2009) Huperzine A protects isolated rat brain mitochondria against beta-amyloid peptide. Free Radic Biol Med 46, 1454-1462.
37. Wang CY, Zheng W, Wang T, Xie JW, Wang SL, Zhao BL, Teng WP, Wang ZY (2011) Huperzine A activates Wnt/beta-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model. Neuropsychopharmacology 36, 1073-1089.
38. Zhang JM, Hu GY (2001) Huperzine A, a nootropic alkaloid, inhibits N-methyl-D-aspartate-induced current in rat dissociated hippocampal neurons. Neuroscience 105, 663-669.
39. Wang J, Zhang HY, Tang XC (2010) Huperzine a improves chronic inflammation and cognitive decline in rats with cerebral hypoperfusion. J Neurosci Res 88, 807-815.
40. Xiao XQ,Wang R, HanYF, TangXC(2000) Protective effects of huperzine A on beta-amyloid(25-35) induced oxidative injury in rat pheochromocytoma cells. Neurosci Lett 286, 155-158.
41. Perry EK, Perry RH, Blessed G, Tomlinson BE (1978) Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 4, 273-277.
42. Darvesh S, Reid AG, Martin E (2010) Biochemical and histochemical comparison of cholinesterases in normal and Alzheimer brain tissues. Curr Alzheimer Res 7, 386-400.
43. Mesulam MM, Geula C (1994) Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 36, 722-727.
44. Greig NH, Utsuki T, Yu Q, Zhu X, Holloway HW, Perry T, Lee B, Ingram DK, Lahiri DK (2001) A new therapeutic target in Alzheimer's disease treatment: Attention to butyrylcholinesterase. Curr Med Res Opin 17, 159-165.
45. Darvesh S, MacKnight C, Rockwood K (2001) Butyrylcholinesterase and cognitive function. Int Psychogeriatr 13, 461-464.
46. Yu Q, Holloway HW, Utsuki T, Brossi A, Greig NH (1999) Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease. J Med Chem 42, 1855-1861.
47. Liu J, Zhang HY, Tang XC, Wang B, He XC, Bai DL (1998) Effects of synthetic (-)-huperzine A on cholinesterase activities and mouse water maze performance. Zhongguo Yao Li Xue Bao 19, 413-416.